Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Identifying Barriers to Medications Adherence and Outpatient Follow-up After Transient Ischemic Attack: A Cross-sectional study
Cerebrovascular Disease and Interventional Neurology
P3 - Poster Session 3 (5:00 PM-6:00 PM)
5-006
To evaluate adherence to secondary stroke prevention medications (antiplatelet and/or statin) and outpatient follow-up after TIA discharge, along with identifying barriers to noncompliance and loss to follow-up.
Adherence to secondary stroke prevention and timely outpatient follow-up is essential to reduce the risk of subsequent stroke following a TIA. However, reasons for medication noncompliance or loss of follow-up remains poorly understood. 
We conducted a survey of patients discharged after TIA (April 2024–2025) evaluating compliance with antiplatelet and statin therapy, rate of outpatient follow-up, and reasons for noncompliance or loss to follow-up. Understanding of diagnosis and rationale behind medications was measured with a 3-point Likert scale. Demographic data were collected retrospectively. Logistic regression with Fisher’s exact tests identified predictors of follow-up. 

Of 88 eligible patients, 66 (75%) completed the survey. Noncompliance with antiplatelet and/or statin therapy occurred in 24.2% (n=16), while 19.7% (n=13) were lost to follow-up. Reported reasons for noncompliance included belief medication was not necessary (25%), side effects without physician input (18.7%), physician-advised discontinuation (18.7%), and forgetfulness (12.5%). Among those lost to follow-up, 76.9% felt follow-up was not necessary and 23.1% cited insurance barriers. Regarding understanding, 10.6% disagreed and 22.7% somewhat agreed with “I understand my diagnosis of TIA.” For medication rationale, 21.1% somewhat agreed and none disagreed with “I understand the rationale for prescribed stroke prevention medications.”  

Medication-compliant patients were likely to attend outpatient follow-up (OR 6.17; 95% CI: 1.56–24.42; p<0.005), while other demographic data and cardiovascular risk factors were not significantly associated with compliance. 
About one in five TIA patients were non-adherent to secondary prevention medication or lost to follow-up, most often because patients decided it was not needed. Nearly one-third reported limited understanding of their diagnosis, highlighting the need for improved methods for patient counseling. Study limited by a small sample size.
Authors/Disclosures
Chetna Dengri, MD
PRESENTER 		Dr. Dengri has a non-compensated relationship as a Trainee board member with Neurology Â鶹´«Ã½Ó³»­ Journal Editorial Board that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Muaz Ali, MD Dr. Ali has nothing to disclose.
Paola V. Oyola Miss Oyola has nothing to disclose.
Amre Nouh, MD, FÂ鶹´«Ã½Ó³»­ (Cleveland Clinic) Dr. Nouh has stock in Openwater.